Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi Biologics

Division of WuXi PharmaTech Inc.
www.wuxibiologics.com

Latest From WuXi Biologics

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

Coronavirus Update: BIO Facilitates COVID-19 Collaborations, ASCO Goes Virtual

BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.

Coronavirus COVID-19 Infectious Diseases

Vir Advances Antibodies Against COVID-19, CEO Scangos Leads BIO’s Coronavirus Outreach

Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.

Coronavirus COVID-19 Business Strategies

Coronavirus Update: Trump Spreads Confusion On Drug Treatments, Biogen Fires China Flight Employee

Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.

Coronavirus COVID-19 Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • WuXi PharmaTech Inc.
  • Senior Management
  • Zhisheng Chen, PhD, CEO
    Christine Lu-Wong, EVP, CFO
    Weichang Zhou, PhD, SVP, CTO
  • Contact Info
  • WuXi Biologics
    Phone: 510 8183 1205
    108 Meiliang Road. W
    MaShan Binhu
    Wuxi , 214092
    China
UsernamePublicRestriction

Register